In summary, our study is the first to indicate the potential role of Smurf2 as a common modulator of resistance and to identify Smurf2 as a potential novel actionable target that can improve responses to both cisplatin and radiation therapy in lung cancer. Here, SMURF2 is linked to lung cancer.